The KAT7 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma cell line, engineered to disrupt the KAT7 gene. This genetically diverse pool of edited cells provides a robust loss-of-function model for investigating the functional consequences of KAT7 ablation in colorectal cancer contexts, circumventing the clonal selection bias inherent in monoclonal cell lines.
HT29 is a well-characterized human colorectal adenocarcinoma cell line with epithelial morphology, widely employed as a model system for intestinal epithelial biology, drug transport studies, and colorectal cancer research. Its predictable growth kinetics and responsiveness to differentiation agents make it an ideal host for gene knockout studies.
KAT7 (MYST2/HBO1) encodes a histone acetyltransferase that preferentially acetylates histones H3 and H4 at replication origins, thereby licensing DNA replication and regulating chromatin remodeling. KAT7 operates within multiprotein complexes containing JADE1, ING4, EAF6, and BRPF2, and its enzymatic activity is governed by upstream regulators including E2F1, CDK2, and ING5. Downstream, KAT7-mediated acetylation promotes MCM2-7 helicase loading via interactions with ORC1 and CDT1, and directly acetylates TP53 at key residues, modulating p53 transcriptional activity. Additionally, KAT7 influences expression of cell cycle regulators such as CCND1, linking epigenetic modification to cell proliferation control.
In colorectal adenocarcinoma, disruption of KAT7 impairs histone acetylation dynamics, leading to defective DNA replication licensing and perturbed cell cycle gene expression, which can attenuate the proliferative capacity of HT29 cells. The concurrent alteration of p53 acetylation status may further modulate apoptosis or cell cycle arrest, highlighting the model??s utility for dissecting epigenetic contributions to tumorigenesis and exploring therapeutic vulnerabilities in colorectal cancer.
This polyclonal knockout cell product is suitable for a broad range of assays, including Western blotting and ChIP-qPCR to assess histone acetylation changes, RT-qPCR for cell cycle gene profiling, flow cytometry-based cell cycle and apoptosis analyses, and MTT or colony formation assays to measure proliferation. The heterogeneous population enables transcriptome-wide RNA-seq studies and high-throughput screening of epigenetic inhibitors, providing a versatile tool for functional validation of KAT7 in colon adenocarcinoma. For further technical assistance or to discuss custom applications, please contact Ascent Research.
